A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Inclusion Criteria: * Signed Informed Consent Form. * Age 18 years or older at the time of signing the Informed Consent Form. * Histologically proven diffuse large B-cell lymphoma (DLBCL), including transformation from follicular lymphoma. * Relapsed or refractory disease after first-line chemoimmunotherapy, defined as refractory disease (no complete remission to first-line therapy, progressive disease as best response, stable disease after 3-4 cycles, or partial response after 6-8 cycles/progression within 12 months of first-line therapy) or relapsed disease (complete remission followed by biopsy-proven relapse within 12 months of first-line therapy). * No known history or suspicion of central nervous system (CNS) involvement by lymphoma. * Life expectancy of at least 12 weeks. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * At least one bi-dimensionally measurable nodal lesion (1.5 cm or larger) or extranodal lesion (1 cm or larger) as measured on a CT scan. * Negative HIV test at screening. * Adequate hematologic function defined as hemoglobin 9.0 g/dL or higher without transfusion in the past 7 days, absolute neutrophil count 1.0 x 10\^9/L or higher, and platelet count 75 x 10\^9/L or higher. * Adequate organ function defined as estimated creatinine clearance 60 mL/min or higher, ALT/AST 2.5 times the upper limit of normal (ULN) or lower, and total bilirubin 1.5 mg/dL or lower (or 3 x ULN or lower in subjects with Gilbert's syndrome). * Cardia…